Skip to main content
Fig. 1 | Respiratory Research

Fig. 1

From: Treatment response to indacaterol/glycopyrronium versus salmeterol/fluticasone in exacerbating COPD patients by gender: a post-hoc analysis in the FLAME study

Fig. 1

Annualized rate of moderate/severe and all (mild/moderate/severe) exacerbations. n, number of patients included in the analysis; N, total number of patients in the study. b.i.d., twice daily; CI, confidence interval; IND/GLY, indacaterol/glycopyrronium 110/50 μg o.d.; o.d., once daily; SFC, salmeterol/fluticasone 50/500 μg b.i.d

Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us